Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Letter to the Editor

Seroprevalence of IgM and IgG Antibodies against SARS-CoV-2 in Asymptomatic People in Wuhan: Data from a General Hospital Near South China Seafood Wholesale Market during March to April in 2020

LING Rui Jie¹,², YU Yi Han¹,², HE Jia Yu³, ZHANG Ji Xian¹, XU Sha¹, SUN Ren Rong¹, ZHU Wang Cai¹, CHEN Ming Feng², LI Tao²,¹,JI Hong Long³, and WANG Huan Qiang²,³

The aim of this study was to estimate the seroprevalence of immunoglobulin M (IgM) and G (IgG) antibodies against SARS-CoV-2 in asymptomatic people in Wuhan. This was a cross-sectional study, which enrolled 18,712 asymptomatic participants from 154 work units in Wuhan. Pearson Chi-square test, t-test, and Mann-Whitney test were used to compare the standardized seroprevalence of IgG and IgM for age and gender between different groups. The results indicated the standardized seroprevalence of IgG and IgM showed a downward trend and was significantly higher among females than males. Besides, different geographic areas and workplaces had different seroprevalence of IgG among asymptomatic people, and the number of abnormalities in CT imaging were higher in IgG antibody-positive cases than IgG-negative cases. We hope these findings can provide references for herd immunity investigation and provide basis for vaccine development.

Key words: COVID-19; SARS-CoV-2; Serological testing; IgG; IgM; Seroprevalence; Computed tomography

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused coronavirus disease 2019 (COVID-19) pandemic in the early 2020. Quantitative reverse transcription-polymerase chain reaction (RT-PCR) test, a two-step method used for detection of ribonucleic acid (RNA), was a gold standard in COVID-19 diagnosis[1]. However, many patients can be asymptomatic due to the clinical spectrum of SARS-CoV-2 infection[2]. The SARS-CoV-2-specific antibodies appear around 3–10 days after infection, with IgM appeared first and IgG followed[3]. Previous serological studies about SARS-CoV-2 mainly focusing on health-care workers or blood donors, which based on small or non-random sampling[4,5]. To increase the accuracy of estimation about seroprevalence of IgG and IgM against SARS-CoV-2 among asymptomatic people in Wuhan, our study not only considered the test performance, but also adjusted for age and gender of the general population.

A cross-sectional study was conducted in a general hospital near the Huanan Seafood Wholesale Market to conduct a serological survey using a validated assay targeting on spike and nucleocapsid protein for IgM and IgG antibodies against SARS-CoV-2[6]. After the outbreak of COVID-19 in Wuhan, residents were asked to do the SARS-CoV-2 nucleic acid tests (NAT) of nasopharyngeal swabs, chest CT scans or a SARS-CoV-2-specific serological test before resume work. We selected a serology test that has been fully validated using serum from confirmed COVID-19-infected individuals and well-characterized reference samples[6]. In this hospital, 18,712 medical examination records including IgM and IgG tests for SARS-CoV-2 antibodies and other tests were analysed among people with no fever, headache or other symptoms of COVID-19 from March 25 to April 28, 2020.

Clinical data we collected including birth date, gender, occupation, residential district, date of test, serum IgG and IgM positive or negative results for SARS-CoV-2 antibodies, nucleic acid testing, clinical symptoms, chest CT and laboratory tests. Only 1,636 of the subjects had chest CT and 12,481 subjects had the laboratory tests. SARS-CoV-2 antibody detection

doi: 10.3967/bes2021.103

This work was supported by Advisory Research Project of the Chinese Academy of Engineering in 2019 [2019-XZ-70].

1. Integrated Chinese & Western Medicine, Hubei Provincial Hospital, Wuhan 430030, Hubei, China; 2. National Institute of Occupational Health and Poison Control, Chinese Center for Disease Control and Prevention, Beijing 100050, China; 3. Department of Cellular and Molecular Biology, University of Texas Health Science Centre, Tyler 75708, TX, U.S.
kits (colloidal gold method) were provided by INNOVITA (Tangshan, registration certificate for the medical devices of Peoples Republic of China: 20203400177). All enrolled medical examiners collected 2 mL peripheral venous blood. After centrifugation, serum was taken for SARS-CoV-2-specific IgG and IgM antibody detection within 2 h. Nasopharyngeal or oropharyngeal swabs used for SARS-CoV-2 nucleic acid testing were collected by trained and qualified medical staff to perform NAT within 2 h and read the results within 15 min. The automatic nucleic acid extraction instrument was provided by the Hangzhou Allsheng Instruments Co. Ltd. (Allsheng). The ABI-7500 fluorescence PCR instrument was from Thermo Fisher Scientific Inc. All operations were carried out according to kit instructions.

All analyses were conducted using SPSS software (version 22.0, IBM Corporation, Armonk, NY, USA), the R software package (version 3.6.2; 2019, The R Foundation for Statistical Computing), and GraphPad Prism (Version 8.0, GraphPad Software, LLC, La Jolla, CA, USA). Proportions for categorical variables were compared either by Pearson Chi-square test or by Fisher’s Exact Test. Statistical analysis of continuous variables utilized means with standard deviation(s) for normally distributed data and medians with interquartile range (IQR) for non-normally distributed data. Means for continuous variables were compared via independent group t-tests when the data were normally distributed; otherwise, the Mann-Whitney test was used. P < 0.05 was considered statistically significant. To correct for the effects of gender and age, the seroprevalence of IgM positivity, IgG positivity, and IgM and/or IgG positivity were standardized according to the gender and age-specific population of Wuhan in 2017 (Supplementary Table S1, available in www.besjournal.com). To correct for effects from accuracy of the serum antibody test, seroprevalence was corrected according to the sensitivity and specificity of the colloidal gold test in previous studies following the Rogan and Gladen method[1].

The demographic distribution of participants who enrolled in our study was a little different from that of Wuhan (Supplementary Figure S1, available in www.besjournal.com). Participants aged under 19 and over 65 in this study was much smaller than the general population. Among those enrolled, 11,391 (60.9%) were male and 7,321 (39.1%) were female. The median age of the subjects was 40 years (IQR, 22–50; range, 4–81), with the majority (n = 17,367, 92.8%) aged 25 to 59 years. The cumulative count of the population tested for antibodies against SARS-CoV-2 and the number of positive cases of IgG and IgM are shown in Supplementary Figure S2, available in www.besjournal.com.

**Supplementary Table S2** (available in www.besjournal.com) shows the unadjusted, age- and gender- adjusted (standardized according to the number of people of different ages and gender in the population of Wuhan from the national census of 2017), and assay adjusted (adjusted for age, gender, and test sensitivity and specificity performance) seroprevalence for IgG and IgM against SARS-CoV-2 in asymptomatic people by gender. The seroprevalence of IgG in females was significantly higher than in males (unadjusted: $\chi^2 = 6.53, \ P = 0.011$; age- and gender- adjusted: $\chi^2 = 20.43, \ P < 0.001$). However, both the unadjusted and age- and gender- adjusted seroprevalence of IgG were not significantly different between genders. When analysed IgG and IgM positivity together, the seroprevalence of IgG and/or IgM in females was significantly higher than in males (unadjusted: $\chi^2 = 7.19, \ P = 0.007$; age- and gender- adjusted: $\chi^2 = 21.91, \ P < 0.001$). Additionally, the assay adjusted seroprevalence for IgG and/or IgM was also significantly higher for females than males ($\chi^2 = 35.702, \ P < 0.001$). Based on the census of Wuhan population aged 4–81 years in 2017, we estimated the number of asymptomatic COVID-19-positive individuals aged 4–81 years in Wuhan was 217,332 (95% CI: 198,709–235,955) from March 25 to April 28, 2020. The seroprevalence of IgG and odds ratio arranged by time series were listed in Supplementary Table S3, available in www.besjournal.com. In the first period, we estimated the seroprevalence of IgG at 3.82% (95% CI: 2.18–5.47, n = 523). The estimation increased to 8.43% (95% CI: 6.87–9.99, n = 1,222) in the third period, and then decreased. The lowest estimated seroprevalence of IgG was 1.45% (0.93–1.98, n = 1,998) in the last period. The positivity for IgM over the same time frame declined slightly and remained at a low level, with the highest rate at 1.34% (0.35–2.32) in the first period, which dropped to a low of 0.28% (0.07–0.48) in the sixth period (Supplementary Table S4, available in www.besjournal.com).

The distribution of the adjusted seroprevalence of IgG and IgM in the time series, and the distribution of the crude seroprevalence of IgG and IgM in different age groups are in Figure 1. The
Seroprevalence of antibodies against SARS-CoV-2

Seroprevalence of IgG or IgM in different testing time periods was correlated with time periods ($\chi^2 = 153.88, P < 0.001$; $\chi^2 = 17.08, P = 0.009$). Although none of the 26 individuals under the age of 19 years tested positive for IgG, no significant correlation was observed between the seroprevalence of IgG and the different age groups ($\chi^2 = 11.54, P = 0.292$). In contrast, the seroprevalence of IgM was significantly correlated with different age groups ($\chi^2 = 18.50, P = 0.035$), showing a higher seroprevalence in the middle-aged group for men and an increased seroprevalence with age for women. No IgM positivity was detected in males or females under 24 years old. The positivity for IgM antibodies in males over 55 years old was significantly lower than for females.

The crude seroprevalence and odds ratio by geographic areas from different types of workplaces are shown in Table 1. A significant difference was seen in seroprevalence of IgG by urban area ($\chi^2 = 42.87, P < 0.001$), but not observed for IgM ($\chi^2 = 14.73, P = 0.069$). The Wuchang and Jianghan districts had higher seroprevalence of IgG than other urban areas. Among the 154 work units, 57.8% (89/154) had at least one positive case of IgG or IgM among employees, accounting for 92.5% (17,315/18,712) of the number of antibody-positive individuals, including a water supply company, a real estate company, and telecommunications companies. A significant difference was seen in the seroprevalence of IgG and IgM among people from different work units (IgG: $\chi^2 = 202.43, P < 0.001$; IgM: $\chi^2 = 28.92, P = 0.001$).

Among the tested individuals, the seroprevalence of IgG was highest for those who voluntarily came for serology test by themselves, followed by those encouraged by their work units. Supplementary

Figure 1. Distributions of seroprevalence of IgG and IgM in asymptomatic individuals in time series and age groups. (A) The seroprevalence with 95% CI of IgG adjusted for age in male and female asymptomatic individuals from March 25 to April 28, 2020 in Wuhan, China. (B) The seroprevalence with 95% CI of IgM adjusted for age in male and female asymptomatic individuals from March 25 to April 28, 2020 in Wuhan, China. (C) The crude seroprevalence with 95% CI of IgG in male and female asymptomatic individuals from ages 4 to 81 in Wuhan, China. (D) The crude seroprevalence with 95% CI of IgM in male and female asymptomatic individuals from ages 4 to 81 in Wuhan, China.
### Table 1. Seroprevalence of IgG and IgM and odds ratio by geographic location (urban and rural areas) and occupation (types of work units)

| Variables                                    | n  | Male, % | Median age in years (IQR) | IgG | P value | IgM | P value |
|----------------------------------------------|----|---------|---------------------------|-----|---------|-----|---------|
|                                              | n1 | % (95% CI) | Odds ratio* (95% CI) | n2 | % (95% CI) | Odds ratio* (95% CI) | P value |
| Urban and rural areas                        |    |          |                          |     |         |     |         |
| Jiangan®                                     | 1,468 | 56.1 | 43 (33–51) | 40 | 2.72 (1.89–3.55) | 1 (ref) | - | 3 | 0.20 (0.00–0.43) | 1 (ref) | - |
| Jianghan                                    | 10,667 | 60.2 | 41 (33–51) | 423 | 3.97 (3.60–4.34) | 1.50 (1.08–2.08) | 0.016 | 58 | 0.54 (0.40–0.68) | 2.76 (0.86–8.83) | 0.087 |
| Huangpi                                      | 1,808 | 53.7 | 31 (26–36) | 39 | 2.16 (1.49–2.83) | 0.86 (0.55–1.35) | 0.512 | 3 | 0.17 (0.00–0.36) | 1.08 (0.22–5.44) | 0.926 |
| Hanyang                                      | 1,515 | 75.6 | 46 (34–53) | 39 | 2.57 (1.77–3.37) | 0.98 (0.62–1.53) | 0.922 | 9 | 0.59 (0.20–0.98) | 2.97 (0.80–11.0) | 0.104 |
| Qiaoqou                                      | 974 | 78.1 | 37 (30–44) | 13 | 1.33 (0.61–2.50) | 0.53 (0.28–1.00) | 0.051 | 2 | 0.21 (0.00–0.50) | 1.22 (0.20–7.34) | 0.831 |
| Wuchang                                      | 884 | 59.2 | 43 (32–51) | 37 | 4.19 (2.87–5.51) | 1.59 (1.01–2.51) | 0.045 | 7 | 0.79 (0.21–1.37) | 4.04 (1.04–15.7) | 0.043 |
| Hongshan                                     | 565 | 45.7 | 39 (30–49) | 14 | 2.48 (1.20–3.76) | 0.91 (0.49–1.69) | 0.767 | 4 | 0.71 (0.02–1.40) | 3.70 (0.82–16.6) | 0.088 |
| Dongxihu                                     | 172 | 80.2 | 46 (34–52) | 4 | 2.33 (0.08–4.58) | 0.89 (0.32–2.52) | 0.829 | 2 | 1.16 (0.00–2.76) | 5.94 (0.98–35.9) | 0.053 |
| Caidian and the others                       | 87 | 72.4 | 39 (33–47) | 4 | 4.60 (0.20–9.00) | 1.84 (0.64–5.26) | 0.258 | 0 | - | - | - |
| Outside                                      | 572 | 46.9 | 42 (33–48) | 14 | 2.45 (1.18–3.72) | 0.89 (0.48–1.64) | 0.704 | 1 | 0.17 (0.00–0.51) | 0.87 (0.09–3.85) | 0.901 |
| Type of work unit                            |    |          |                          |     |         |     |         |
| Primary medical care®                        | 628 | 33.9 | 43 (34–50) | 15 | 2.39 (1.20–3.58) | 1 (ref) | - | 3 | 0.48 (0.00–1.02) | 1 (ref) | - |
| Tap water and natural gas                    | 4,961 | 65.6 | 42 (35–50) | 96 | 1.94 (1.56–2.32) | 0.87 (0.50–1.51) | 0.622 | 21 | 0.42 (0.24–0.60) | 0.97 (0.29–3.29) | 0.961 |
| Real estate                                  | 2,481 | 67    | 41 (32–52) | 147 | 5.93 (5.00–6.86) | 2.78 (1.62–4.79) | <0.001 | 17 | 0.69 (0.36–1.02) | 1.56 (0.45–5.37) | 0.483 |
| Government institutions                      | 2,401 | 66.4 | 44 (35–52) | 59 | 2.46 (1.84–3.08) | 1.09 (0.61–1.94) | 0.762 | 10 | 0.42 (0.16–0.68) | 0.92 (0.25–3.37) | 0.897 |
| The airport                                  | 1,800 | 53.5 | 31 (26–36) | 36 | 2.00 (1.35–2.65) | 1.01 (0.54–1.86) | 0.982 | 3 | 0.17 (0.00–0.36) | 0.50 (0.10–2.53) | 0.401 |
| Banks, securities and insurance companies    | 1,786 | 46.7 | 35 (30–45) | 89 | 4.98 (3.97–5.99) | 2.38 (1.36–4.15) | 0.002 | 17 | 0.95 (0.50–1.40) | 2.43 (0.70–8.37) | 0.161 |
| Highway management and auto repair           | 944 | 76.3 | 47 (35–54) | 41 | 4.33 (3.04–5.64) | 1.99 (1.09–3.65) | 0.025 | 8 | 0.85 (0.26–1.44) | 1.87 (0.49–7.17) | 0.361 |
| Telecommunications companies                 | 750 | 45.2 | 35 (31–40) | 45 | 6.00 (4.30–7.70) | 2.96 (1.63–5.38) | <0.001 | 1 | 0.13 (0.00–0.39) | 0.36 (0.04–3.47) | 0.375 |
| Law firms, procuratorates                    | 706 | 51.4 | 39 (31–50) | 40 | 5.67 (3.96–7.38) | 2.64 (1.44–4.83) | 0.002 | 2 | 0.28 (0.00–0.67) | 0.66 (0.11–3.98) | 0.652 |
| Rehab                                        | 700 | 72.7 | 45 (36–51) | 15 | 2.14 (1.07–3.21) | 0.97 (0.47–2.00) | 0.925 | 5 | 0.71 (0.09–1.33) | 1.62 (0.38–6.58) | 0.514 |
| Other service industries                     | 1,501 | 60.4 | 39 (31–49) | 33 | 2.20 (1.46–2.94) | 1.01 (0.54–1.88) | 0.978 | 1 | 0.07 (0.00–0.20) | 0.16 (0.02–1.53) | 0.112 |
| Personal                                     | 54 | 61.1 | 42 (32–49) | 11 | 20.4 (9.63–31.1) | 11.5 (4.95–26.6) | <0.001 | 1 | 1.85 (0.00–5.44) | 4.40 (0.45–43.3) | 0.204 |

**Note.** n is the total number of individuals; n1 is the number of IgG-positive individuals; n2 is the number of IgM-positive individuals; IQR is interquartile range. *Odds ratios were adjusted for age and gender. ®Jianghan district and primary medical care were the reference group to which other groups were compared. Real estate includes real estate agencies, residential property management firms and urban construction corporations.
Figure S3 (available in www.besjournal.com) shows the geographic distribution of the seroprevalence of IgG or IgM antibody against SARS-CoV-2 in asymptomatic people from March 25 to April 28, 2020, in Wuhan, China.

The relationship between abnormal chest CT imaging and the seroprevalence of IgG and IgM antibodies for different age groups was shown (Supplementary Figures S4–S5, available in www.besjournal.com). Of the participants, 1,636 underwent chest CT, and 342 had abnormal images. CT imaging abnormality was significantly different ($\chi^2 = 17.74$, $P < 0.001$) between people who were IgG antibody-positive (30.7%, 94/306) and IgG antibody-negative (19.7%, 262/1,330). Among the IgG-positive patients, typical abnormal chest CT signs were ground glass opacity (GGO)s, GGOs with small mixed consolidation, and prominent peripheral subpleural distribution (Figure 2). Significant differences were seen between IgG and/or IgM-positive test groups in leukocytes, neutrophilic granulocytes and monocyte percentage (Supplementary Table S5, available in www.besjournal.com).

Detection of asymptomatic or subclinical SARS-CoV-2 infection is critical for understanding the overall prevalence and infection potential of COVID-19. In the early 2020, studies showed the seroprevalence of anti-SARS-CoV-2 antibodies were 4.8%–10.9% in Geneva, Switzerland\(^8\) and around 5.0% (4.7%–5.4%) in Spain\(^6\), which demonstrated most population remained unexposed. In China, the seroprevalence among the general population was only 3.35%. Additionally, the reported confirmed patients was up to 50,333 in Wuhan until April 28. Therefore, we estimated there were at least 4.1 (204,548/50,333) asymptomatic infections for every reported confirmed case in the general population, which was smaller than the estimate of the Switzerland study (11.6 infections per reported confirmed case in the community).

This study showed there were differences in IgG seroprevalence among urban and rural areas, which were much higher in Wuchang District and Jianghan District than in other areas. Based on the cumulative number of reported cases of COVID-19 from March 25 to April 28, and the number of residents in each district in Wuhan, we estimated an average incidence rate per 100,000 people of 2.98 (95% CI: 2.97–2.99) during this period. Incidence rates were higher in the Jianghan and Wuchang districts, at 8.09 (95% CI: 8.02–8.15) and 7.25 (95% CI: 7.20–7.29) per 100,000 people, respectively, which show that seropositive rates in different geographic areas were consistent with the spread of the SARS-CoV-2 coronavirus in Wuhan (Supplementary Table S6 and Supplementary Figure S6, available in www.besjournal.com).

Additionally, the highest seroprevalence of IgG was in those people who voluntarily came for serology testing by themselves, most of whom had close contacts with COVID-19 patients and therefore had a higher risk of infection. Our study found significant aggregation of asymptomatic infections in individuals from certain occupations.

Figure 2. CT imaging of one asymptomatic individual positive for IgG. (A) shows a platelet of GGO in the posterior segment of the upper lobe of the left lung. (B) shows GGOs with small mixed consolidation in the posterior basal segment of the lower lobe of both lungs, and the pleural offline was seen in the posterior basal segment of the lower lobe of the left lung. GGO, ground glass opacity.
The groups in some industries with high IgG seroprevalence were easy to identify due to the nature of their jobs, such as insurance and securities professionals located in the higher risk districts, which faced a greater chance of contacting infected people during their work. Besides, we also found the IgG seroprevalence was higher in females than in males, indicating that females were more likely to have asymptomatic infections. This was consistent with previous studies. Finally, the most common CT features in patients affected by COVID-19 include GGO and consolidation involving the bilateral lungs in a peripheral distribution. The CT imaging which we observed demonstrated similar differences between IgG antibody-positive and negative individuals, reminding some damage may have occurred in some asymptomatic individuals positive for IgG antibodies.

This investigation had a few limitations. First, there were selection bias since the analysed medical records were based on examinees directed by their work units. Most of the examinees came from government-owned institutions and agencies instead of private businesses. Therefore, the sample was incompletely randomized and insufficiently representative, compromising the assessment accuracy of the prevalence of asymptomatic infections in Wuhan. Second, as the examinees were only from the back-to-work population, people under the age of 19 and over age 65 were too few to be fully covered in analyses. However, the strength of this study includes being designed as repeated five-day serosurveys, which allowed for the monitoring of seroprevalence progression just after the end of the first epidemic. Furthermore, our study applied scientific statistical methods accounting for the demographic structure of the general population and diagnostic tests to estimate seroprevalence in the overall population, while capturing uncertainty in the estimates.

Our study verified most population remains susceptible to COVID-19 in Wuhan. We also found significant aggregation of asymptomatic infections from certain occupations and slight damage may occurred in infections CT imaging. Thus, we recommend the prevention strategies should focusing on high risk populations and the CT imaging should not use as the only diagnosing method. Moreover, we hope the study of IgG and IgM against SARS-CoV-2 among asymptomatic infections can provide scientific basis for vaccine development.

Acknowledgements We acknowledge the work and contribution of all the health care providers from the Hubei Provincial Hospital of Integrated Chinese & Western Medicine.

Ethical Approval and Consent to Participate This study was approved by the Ethics Committee of the Hubei Provincial Hospital of Integrated Chinese & Western Medicine [No. 2020011]. Waiver of informed consent for collection of epidemiological data from individuals tested for COVID-19 was granted by the National Health Commission of China as part of the infectious disease outbreak investigation. All identifiable personal information was removed for privacy protection when data were extracted.

Author Contributors LRJ, YHY, WHQ, and LT were responsible for study design. LRJ, YHY, WHQ, and HJY were responsible for the literature search. LRJ, YHY, ZIX, XS, SRR, ZWC, WHQ, and CMF were responsible for data collection. WHQ was responsible for data analysis. WHQ and CMF were responsible for figures. WHQ, JHL, and LT were responsible for data interpretation. WHQ, HJY, JHL, LRJ, and YHY were responsible for writing the first draft of the manuscript. All authors contributed to the final draft.

Conflict of Interest No potential conflict of interest was reported by the authors. The funder had no role in study design, data collection, data analysis, interpretation or writing of the report.

These authors contributed equally to this work.

Correspondence should be addressed to WANG Huan Qiang, PhD; Tel: 86-10-83132825, E-mail: wanghaiqiang@niohp.chinacdc.cn; JI Hong Long, PhD, Tel: 86-903-8777418, E-mail: James.ji@uthct.edu; LI Tao, Master of Medicine, Tel: 86-10-83132513, E-mail: litao@chinacdc.cn

Biographical notes of the first authors: LING Rui Jie, male, born in 1966, Chief Physician, majoring in occupational diseases prevention; YU Yi Han, male, born in 1976, Associate Chief Physician, majoring in respiratory diseases treatment.

Received: September 28, 2020;
Accepted: February 23, 2021

REFERENCES

1. Bustin SA, Nolan T. RT-qPCR testing of SARS-CoV-2: a primer. Int J Mol Sci, 2020; 21, 3004.
2. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med, 2020; 382, 1708–20.
3. Zhao JJ, Yuan Q, Wang HY, et al. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clin Infect Dis, 2020; 71, 2027–34.
4. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet, 2020; 396, 535–44.
5. Garcia-Basteiro AL, Moncunill G, Tortajada M, et al.
Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat Commun, 2020; 11, 3500.

6. Zhang WJ, Lv X, Huang C, et al. Clinical evaluation and application of detection of IgM and IgG antibodies against SARS-CoV-2 using a colloidal gold immunochromatography assay. Chin J Virol, 2020; 36, 348−54. (In Chinese)

7. Rogan WJ, Gladen B. Estimating prevalence from the results of a screening test. Am J Epidemiol, 1978; 107, 71−6.

8. Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet, 2020; 396, 313−9.

9. Zeng FF, Dai C, Cai PC, et al. A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: a possible reason underlying different outcome between sex. J Med Virol, 2020; 92, 2050−4.

10. Bao CP, Liu XH, Zhang H, et al. Coronavirus disease 2019 (COVID-19) CT findings: a systematic review and meta-analysis. J Am Coll Radiol, 2020; 17, 701−9.